Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
D2DR/Dopamine D2 Receptor CRISPR/Cas9 KO Plasmid (m): sc-420053
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- D2DR/Dopamine D2 Receptor CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the D2DR/Dopamine D2 Receptor genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: D2DR/Dopamine D2 Receptor Antibody (B-10): sc-5303
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
D2DR/Dopamine D2 Receptor CRISPR/Cas9 KO Plasmid (m) | sc-420053 | 20 µg | $397.00 |
Overview
Drd2 encodes the dopamine D2 receptor (D2DR), a Gi/o-coupled GPCR that modulates neuronal excitability and synaptic transmission by inhibiting adenylyl cyclase, reducing cAMP/PKA signaling, and regulating ion channel activity. D2DR also influences MAPK/ERK and PI3K-related pathways and acts as an autoreceptor controlling dopamine release and synthesis in dopaminergic circuits. In mouse brain, Drd2 contributes to striatal and corticolimbic signaling underlying motivation, reward learning, and motor control. Dysregulated D2DR signaling has been implicated in neuropsychiatric and movement disorder biology, making Drd2 a widely used target for mechanistic studies of dopaminergic circuitry and receptor-mediated signaling.
D2DR/Dopamine D2 Receptor CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Drd2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Drd2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Drd2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish D2DR/Dopamine D2 Receptor protein expression.
This CRISPR knockout system enables efficient generation of Drd2-deficient cell models for investigation of D2DR/Dopamine D2 Receptor signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Drd2 exon(s) critical for D2DR/Dopamine D2 Receptor function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Drd2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by D2DR/Dopamine D2 Receptor CRISPR/Cas9 KO Plasmid (m) and D2DR/Dopamine D2 Receptor CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Drd2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by D2DR/Dopamine D2 Receptor HDR Plasmid (m) and D2DR/Dopamine D2 Receptor HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Drd2 homology arms to support homology-directed repair at defined Drd2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.